2,4-thiazolidinedione has been researched along with Thrombophilia in 1 studies
thiazolidine-2,4-dione: structure in first source
1,3-thiazolidine-2,4-dione : A thiazolidenedione carrying oxo substituents at positions 2 and 4.
Thrombophilia: A disorder of HEMOSTASIS in which there is a tendency for the occurrence of THROMBOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A total of 2368 patients with type 2 diabetes mellitus and clinically stable, angiographically documented coronary artery disease were randomized to treatment with 1 of the 2 strategies and followed for an average of 5 years." | 2.76 | Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. ( Brooks, MM; Frye, RL; Genuth, S; Hardison, RM; Huber, K; Krishnaswami, A; McBane, RD; Pratley, RE; Schneider, DJ; Sobel, BE; Wolk, R, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sobel, BE | 1 |
| Hardison, RM | 1 |
| Genuth, S | 1 |
| Brooks, MM | 1 |
| McBane, RD | 1 |
| Schneider, DJ | 1 |
| Pratley, RE | 1 |
| Huber, K | 1 |
| Wolk, R | 1 |
| Krishnaswami, A | 1 |
| Frye, RL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes[NCT00006305] | Phase 3 | 2,368 participants (Actual) | Interventional | 2000-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00006305)
Timeframe: five years
| Intervention | participants (Number) |
|---|---|
| Revascularization and Insulin Providing (IP) | 80 |
| Revascularization and Insulin Sensitizing (IS) | 75 |
| Medical Therapy and Insulin Providing (IP) | 80 |
| Medical Therapy and Insulin Sensitizing (IS) | 81 |
(NCT00006305)
Timeframe: five years
| Intervention | participants (Number) |
|---|---|
| Revascularization and Insulin Providing (IP) | 145 |
| Revascularization and Insulin Sensitizing (IS) | 121 |
| Medical Therapy and Insulin Providing (IP) | 143 |
| Medical Therapy and Insulin Sensitizing (IS) | 140 |
1 trial available for 2,4-thiazolidinedione and Thrombophilia
| Article | Year |
|---|---|
Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
Topics: Adult; Biomarkers; C-Reactive Protein; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Co | 2011 |